1. Cytopathological Heterogeneity of Circulating Tumor Cells in Non-metastatic Esophageal Adenocarcinoma
- Author
-
Kim Grebe, Martha B. Pitman, Birte Kulemann, Jessica Guenzle, Jasmina Kuvendjiska, Sylvia Timme, Verena Martini, Claudia Schmoor, Jens Hoeppner, Clara Braun, Torben Glatz, and Stefan Fichtner-Feigl
- Subjects
Male ,Cancer Research ,Pathology ,medicine.medical_specialty ,Esophageal Neoplasms ,Cell ,Esophageal adenocarcinoma ,Cell Count ,Cell Separation ,Kaplan-Meier Estimate ,Adenocarcinoma ,03 medical and health sciences ,0302 clinical medicine ,Circulating tumor cell ,Biomarkers, Tumor ,Humans ,Non metastatic ,Medicine ,In patient ,Stage (cooking) ,business.industry ,Macrophages ,General Medicine ,Middle Aged ,Neoplastic Cells, Circulating ,Prognosis ,Peripheral blood ,medicine.anatomical_structure ,Oncology ,Cytopathology ,030220 oncology & carcinogenesis ,Female ,business - Abstract
Background/aim The presence of circulating tumor cells (CTC) has been reported to have an impact on prognosis in different tumor entities. Little is known about CTC morphology and heterogeneity. Patients and methods In a multicenter setting, pre-therapeutic peripheral blood specimens were drawn from patients with non-metastatic esophageal adenocarcinoma (EAC). CTCs were captured by size-based filtration (ScreenCell®), subsequently Giemsa-stained and evaluated by two trained readers. The isolated cells were categorized in groups based on morphologic criteria. Results Small and large single CTCs, as well as CTC-clusters, were observed in 69.2% (n=81) of the 117 specimens; small CTCs were observed most frequently (59%; n=69), followed by large CTCs (40%; n=47) and circulating cancer-associated macrophage-like cells (CAMLs; 34.2%, n=40). Clusters were rather rare (12%; n=14). CTC/CAML were heterogeneous in the cohort, but also within one specimen. Neither the presence of the CTC subtypes/CAMLs nor the exact cell count were associated with the primary clinical TNM stage. Conclusion Morphologically heterogenic CTCs and CAMLs are present in patients with non-metastatic, non-pretreated EAC.
- Published
- 2020